Werewolf Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
200 Talcott Ave # 2, Watertown, Massachu...Phone Number
(617) 952-0555Website
www.werewolftx.comRevenue
$21 MillionStock Symbol
HOWLIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treRead more
Werewolf Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Werewolf Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Werewolf Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Werewolf Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Werewolf Therapeutics
Earning: See what the market has to say on Werewolf Therapeutics recently announced quarterly report
Check if Werewolf Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Werewolf Therapeutics had a recent Job posting/layoffs
Werewolf Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Werewolf Therapeutics launches new products
Recommended Actions
Find VP level buyers at Werewolf Therapeutics
Find 2 more new buyers
Compare Similar Companies to Werewolf Therapeutics
Compare insights from companies similar to Werewolf Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Werewolf Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Werewolf Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Werewolf Therapeutics.
Werewolf Therapeutics financials insights
Gather financial insights about Werewolf Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$56M
2021
Series B
$72M
Share Placement
$120M
Werewolf Therapeutics Tech Stack
A closer look at the technologies used by Werewolf Therapeutics
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Project
Accounting, Audit, Financial Reporting, Finance
Werewolf Therapeutics News & Media
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
BALA CYNWYD, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.Werewolf Therapeutics to Merge With Ambros in Stock Deal; Raises $150 Million PIPE ...
Werewolf Therapeutics signed a stock-for-stock merger with Ambros Therapeutics, valuing Ambros at approximately $500 million and implying Werewolf at $47.5 million. Pro forma ownership is expected to be about 71.7% for Ambros holders, 6.8% for existing Werewolf holders, and 21.5% for PIPE investors…Werewolf Therapeutics And Ambros Therapeutics Announce Merger; Secure $150M Financing
Werewolf Therapeutics (HOWL) shares surged 1,431.19% pre-market after announcing an all-stock merger with Ambros Therapeutics. The deal will create a Nasdaq-listed company focused on neridronate for CRPS-1.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Werewolf Therapeutics
Sign Up For FreeTo access detailed company insights
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional pro... Read More
